Please assess the completion status of the following clinical trial:

Trial Title: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven tumor of RCC, MCL or GIST by histology.~* Informed consent signed by patient.~Exclusion Criteria:~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
- 2 (Type: None): Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
- 3 (Type: None): Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
- 4 (Type: None): Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
- 5 (Type: None): Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)

Based on this trial design, predict the completion outcome and termination type (if applicable).